BCR/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase
It is unclear if patients with CML treated with imatinib who fail to achieve BCR/ABL transcript
levels< 10% IS at 3 months ie an early molecular response (EMR) have a better prognosis if …
levels< 10% IS at 3 months ie an early molecular response (EMR) have a better prognosis if …
BCR/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase
N Hamad, HG Lee, S Kamel‐Reid, JH Lipton - American Journal of …, 2014 - infona.pl
It is unclear if patients with CML treated with imatinib who fail to achieve BCR/ABL transcript
levels< 10% IS at 3 months ie an early molecular response (EMR) have a better prognosis if …
levels< 10% IS at 3 months ie an early molecular response (EMR) have a better prognosis if …
BCR/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase.
DD Kim, N Hamad, HG Lee, S Kamel-Reid… - American Journal of …, 2014 - europepmc.org
It is unclear if patients with CML treated with imatinib who fail to achieve BCR/ABL transcript
levels< 10%(IS) at 3 months ie an early molecular response (EMR) have a better prognosis …
levels< 10%(IS) at 3 months ie an early molecular response (EMR) have a better prognosis …
BCR/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase
DDH Kim, N Hamad, HG Lee… - American journal …, 2014 - pubmed.ncbi.nlm.nih.gov
It is unclear if patients with CML treated with imatinib who fail to achieve BCR/ABL transcript
levels< 10%(IS) at 3 months ie an early molecular response (EMR) have a better prognosis …
levels< 10%(IS) at 3 months ie an early molecular response (EMR) have a better prognosis …